Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is a window study where treatment-naïve patients will receive olaparib before definitive
treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP
inhibitor.